Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial

Jean Abraham(Cancer Research UK)
Nature Communications
May 13, 2025
10.1038/s41467-025-59151-0
Cited by 13

Related Papers

(untitled)
|Edinburgh Research Explorer|0|353
Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
|Cancer Research|2024|7
Data from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
|Unknown|2025|1
Modelling drug responses and evolutionary dynamics using triple negative breast cancer patient-derived xenografts
|bioRxiv (Cold Spring Harbor Laboratory)|2023|0
Figure 4 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
|Unknown|2025|0